Ajanta Pharma Ltd (AJANTPHARM)
₹3,579.30
Mkt cap
₹43,906 Cr
P/E ratio
38.70
P/B
9.89
Div yield
0.91%
ROE
27.10%
ROCE
34.50%
EPS (TTM)
₹92.49
Book value
₹362
52W range
2,388–3,718
Sector
Healthcare
Price history
Previous close
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
NSE AJANTPHARMBSE 532331
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−3.74% from high₹3,579
₹2,388+49.86% from low₹3,718
Current
₹3,579.30
Prev close
₹3,516.50
Day
+1.79%
Price performance
1D
+1.79%
1W
+2.13%
1M
+2.08%
3M
+16.40%
6M
+20.32%
1Y
+44.33%
YTD
+21.37%
Financials
Revenue, profit & margin
P/E ratio
38.7×
AJANTPHARM is 10% above the sector median of 35.1×
AJANTPHARM38.7×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,021 | 1,028 | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 | |
| Expenses | 750 | 738 | 791 | 776 | 815 | 875 | 825 | 873 | 951 | 1,026 | 993 | 1,088 | 1,202 | |
| Operating Profit | 271 | 291 | 314 | 278 | 330 | 311 | 321 | 297 | 351 | 328 | 382 | 333 | 424 | |
| OPM % | 27% | 28% | 28% | 26% | 29% | 26% | 28% | 25% | 27% | 24% | 28% | 23% | 26% | |
| Other Income | 32 | 21 | 14 | 36 | 26 | 19 | 30 | 18 | 26 | 59 | 25 | 61 | 71 | |
| Interest | 1 | 2 | 2 | 2 | 1 | 6 | 8 | 6 | 5 | 3 | 5 | 2 | 3 | |
| Depreciation | 33 | 34 | 34 | 34 | 34 | 34 | 36 | 40 | 41 | 43 | 44 | 45 | 44 | |
| Profit before tax | 269 | 276 | 291 | 278 | 322 | 290 | 307 | 269 | 331 | 341 | 359 | 347 | 447 | |
| Tax % | 23% | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% | 24% | 23% | 25% | |
| Net Profit | 208 | 195 | 210 | 203 | 246 | 216 | 233 | 225 | 255 | 260 | 274 | 267 | 334 | |
| EPS in Rs | 16.24 | 15.24 | 16.39 | 15.82 | 19.68 | 17.33 | 18.64 | 18.03 | 20.44 | 20.83 | 21.91 | 21.35 | 26.75 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.71% · closed higher next day 43 of last 63
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 31 Oct '23◦ | 31 Jan '24◦ | 2 May '24◦ | 30 Jul '24◦ | 29 Oct '24 | 30 Jan '25◦ | 30 Apr '25◦ | 28 Jul '25 | 3 Nov '25 | 30 Jan '26 | 5 May '26 | 30 Jul '26 |
| Earnings day | +3.65% | +0.32% | +6.71% | +6.50% | +0.06% | +0.66% | −4.47% | −0.62% | +3.01% | +3.23% | −0.11% | +1.17% |
| +1 day | +3.71% | −0.27% | +8.08% | +10.35% | +2.53% | +1.56% | −4.42% | +1.40% | +5.90% | +3.38% | +6.74% | +2.02% |
| +5 days | +2.16% | +1.32% | +6.42% | +16.16% | +6.61% | +0.82% | −6.22% | −5.32% | +4.56% | +5.86% | +6.58% | +2.18% |
| +15 days | +11.28% | −2.50% | +8.44% | +23.42% | +1.28% | −0.49% | −4.85% | −2.91% | +1.78% | +9.07% | +6.77% | +7.72% |
| +30 days | +7.62% | −2.39% | +6.47% | +34.01% | −3.94% | −3.74% | −2.66% | −6.84% | +5.31% | +9.62% | +6.16% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202663.49%Promoter
Promoters63.49%2.76
FIIs7.68%0.58
DIIs21.80%3.44
Public7.03%0.11
Government0.00%0.01
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| AJANTPHARM | ₹3,513.60 | 38.69 | 43,906 | 0.91% | 334 | +30.89% | 1,626 | +24.82% | 34.51% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts54
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025TranscriptApr 2025PPTApr 2025RECApr 2025TranscriptFeb 2025PPTFeb 2025TranscriptOct 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024TranscriptJan 2024PPTJan 2024
Credit ratings6
Announcements5
Participation In Investor Conference 31 Aug - Ajanta Pharma schedules investor meetings on 16 and 28 September 2026 in New Delhi and BKC.Announcement under Regulation 30 (LODR)-Newspaper Publication 31 Aug - Pls find enclosed newspaper publication for transfer of equity shares to IEPF.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 27 AugDisclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 19 AugDisclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 14 Aug - Promoter Ravi Agrawal released pledge on 54,796 Ajanta Pharma shares on 14 August 2026.